Mardi Dier

Chief Financial Officer

Adamas Pharmaceuticals Inc Ultragenyx Pharmaceutical Inc.ACELYRIN, Inc.Portola Pharmaceuticals Inc Madrigal Pharmaceuticals, Inc.

Insider activity · 24 months0 buys3 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 2 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 1 saleApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€91k

▼ Sales (7 ops.)

€1.4M

Latest filing published 06 Mar 2026 for Madrigal Pharmaceuticals, INC.. Read the official filing

Filing timeline

BuySale

Mardi Dier

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Mardi Dier: trading record in brief

Filings by Mardi Dier span 5 companies, the busiest being Madrigal Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc. and ACELYRIN, Inc. In total, 14 filings cover trades dated from 27 January 2016 to 4 March 2026.

Market trades split into 1 purchase (€91k) and 7 sales (€1.4M). Netting one side against the other leaves €1.3M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 5 share grants and 1 option exercise. Since January 2026: no purchases and 1 sale on the market.

The newest entry dates from 6 March 2026: a share grant, in Madrigal Pharmaceuticals, Inc. The last purchase on record was published on 11 May 2023, which is 1,256 days ago. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.